The Emerging Role of OligoScan Screening in Radiology
By Robert L. Bard, MD, diagnostic imaging specialist
Edited by: Lennard M. Goetze, Ed.D | Roberta Kline, MD
Environmental toxins and heavy metals represent one of the fastest-growing yet consistently under-recognized drivers of chronic disease. Mercury, arsenic, aluminum, lead, cadmium, gadolinium contrast agents, and airborne particulates from industrial and occupational exposures have all been linked to systemic inflammation, endocrine disruption, carcinogenesis, and autoimmune dysregulation.¹⁻³ Traditional laboratory testing for these exposures is slow, invasive, and often incomplete. Metals may deposit in tissues even when blood and urine tests appear normal, leaving clinicians with a blind spot between exposure and disease expression. Dr. Robert Bard emphasizes that modern environmental medicine requires faster screening, earlier suspicion, and imaging-based confirmation to change outcomes before irreversible pathology takes hold.
PERORMANCE TEST:
OligoScan, a non-invasive spectrophotometric device that analyzes mineral
balance and toxic metal burden through the skin in minutes, offers a promising
first step in a two-tier testing strategy. OligoScan is not a diagnostic device; it is a nutritional and biochemical assessment tool. Its purpose is not to diagnose disease—such as cancer, cardiovascular disorders, or diabetes—but rather to evaluate mineral balance and detect excessive accumulation of toxic metals in peripheral tissues. Using spectrophotometric analysis through the skin, OligoScan provides a rapid, non-invasive overview of an individual’s micronutrient and heavy-metal profile.
This data helps clinicians identify deficiencies that may contribute to metabolic dysfunction or toxic overload that may impair organ systems. Minerals such as zinc, selenium, magnesium, and chromium are essential cofactors for countless enzymatic and hormonal processes. For example, a patient with diabetes who is found to have significantly low chromium may be missing a critical regulatory component for glucose metabolism and insulin sensitivity. Similarly, an excess of mercury, lead, or arsenic in the tissues can interfere with endocrine and neurological function.
SCANNING FOR "GOOD & BAD" ELEMENTS
Aluminum (Al) Antimony
(Sb)
Arsenic (As Barium
(Ba)
Beryllium (Be) Bismuth
(Bi)
Cadmium (Cd) Lead
(Pb)
DAY 1: OLIGOSCAN AS A SCREENING TOOL FOR METAL BURDEN AND
MINERAL IMBALANCE
Dr. Bard identifies several
clinical advantages that make OligoScan valuable as the front end (screening) of a health exam protocol:
·
Non-invasive and painless
·
Results in minutes instead of days or
weeks
·
Ability to repeat frequently for
monitoring
·
Simultaneous assessment of
essential minerals and toxic metals
Unlike traditional tests, OligoScan distinguishes beneficial minerals—such
as zinc, magnesium, selenium, copper, and iron—from toxic metals
including mercury, arsenic, cadmium, aluminum, and lead.
This distinction is biologically critical. Mineral ratio imbalance contributes to oxidative stress, fibrosis, hepatic injury, immune dysregulation, and inflammatory skin disease, while toxic metals directly accumulate in soft tissue, endocrine organs, and microvascular beds.
Dr. Bard notes that exposure risk is especially elevated in:
·
First responders, who inhale,
absorb, and ingest particulates from fires, wreckage, and combustion materials
·
Military personnel
·
Dental and surgical implant patients
·
Individuals with high fish intake
(mercury)
·
Patients repeatedly exposed to
gadolinium through MRI contrast
OligoScan’s speed allows clinicians to identify biochemical red flags and
immediately decide where to look and what to image next.
PART 2
FROM SCREENING TO DIAGNOSTIC CERTAINTY:
THE ROLE OF
ULTRASOUND
OligoScan does not diagnose
disease—its value is in directing what must be confirmed, ruled out, or
mapped anatomically. Dr. Bard emphasizes ultrasound as the superior
next step because it is:
·
Real-time
·
Radiation-free
·
Able to visualize tissue architecture,
vascularity, inflammation, fibrosis, and calcifications
In cases where metal toxicity is suspected, ultrasound can reveal:
·
Dermal and subdermal deposits
·
Fibrotic tissue changes
·
Microcalcifications
·
Microvascular abnormalities
·
Endocrine damage, including early
autoimmune thyroid changes
This is where screening becomes diagnosis.
THE “STARRY NIGHT” PHENOMENON IN HIGH-RESOLUTION ULTRASOUND
High-resolution ultrasound has
transformed dermatologic imaging by allowing clinicians to visualize
architectural and biochemical changes in the skin at the micron level. Common
dermatologic conditions—including arsenical keratosis, melanosis, leukomelanosis,
and hyperkeratosis—demonstrate reproducible sonographic patterns when
inflammation, scarring, or mineral deposition is present.
·
Arsenical keratosis often
produces hyperkeratotic plaques that can eventually calcify; on ultrasound
these appear as dense, bright echogenic foci corresponding to
surface plaques and underlying mineral changes.
·
Melanosis (hyperpigmentation)
results from pigment and inflammatory injury that can thicken and stiffen the
dermis. These regions may develop microcalcifications or fibrotic
strands beneath the surface as a response to chronic irritation or
toxic insult.
·
Leukomelanosis, by contrast,
presents as hypopigmented macules on the surface, but deeper layers may show dermal
scarring and early fibrosis, detectable before the condition becomes
clinically advanced.
·
Hyperkeratosis, particularly on
the palms and soles, can lead to significant thickening. When chronic, it forms
fissures, scarring, and occasional calcific points, which are
readily identified by ultrasound due to their high echogenic contrast.
While these conditions create larger focal abnormalities, advances in digital transducer technology have revealed a second category of findings—microparticulate signatures not visible to the naked eye. Beginning in 2015, European imaging groups reported that modern 18–70 MHz ultrasound could reliably detect structures as small as 50 microns, approximately 1/20th of a millimeter, including metallic microparticles, micro-calcifications, and fibrotic echo clusters.
Dr. Bard refers to the resulting pattern as a “Starry Night”,
a visual constellation of punctate, hyper-echogenic dots distributed through
the dermis and subdermis. Unlike the larger calcifications of keratosis or
trauma scarring, Starry Night reflects micro-debris and micro-damage—often
from:
·
toxic metal deposition
·
environmental particulates
·
dermal injury from chronic inflammation
·
early post-injury fibrosis
· micro-necrotic changes seen in aggressive tumors
With modern elasticity mapping and Doppler correlation, the Starry Night
signature provides three critical diagnostic advantages:
1. Early
Detection – identifying microscopic pathology before macroscopic skin
changes appear
2. Source
Differentiation – distinguishing calcific scarring from metallic
particulate deposition or malignancy-associated changes
3. Aggression
Assessment – when paired with microvascular Doppler, Starry Night
density correlates with inflammatory or tumor activity
In environmental exposure and oncology alike, this micron-level visibility allows clinicians to see the damage that toxins leave behind—bridging the gap between biochemical suspicion and anatomical proof.
INTEGRATION WITH ELASTOGRAPHY AND LONG-TERM MONITORING
Elastography adds a quantitative
measurement of stiffness, allowing clinicians to track:
·
Fibrosis from chronic inflammation
·
Regression of toxicity after detox
protocols
·
Response to focal therapies
This creates a full closed-loop system:
Screen (OligoScan) → Diagnose and Map (Ultrasound + Doppler +
Elastography) → Monitor (Repeat OligoScan + Imaging)
DETOXING TECHNIQUES (part 1)
PROVOCATIVE CHELATION PREDICTORS & TREATMENTS: DMSA , EDTA & DMPS
Basic cellular biology dictates that our circulatory system travels all minerals and nutrients through our bloodstream. In best cases, our immune system should maintain the distribution balance of all these minerals from any potential overload. This overload may reach toxic (and hazardous) levels- whereas solutions such as CHELATION THERAPY may be recommended.
Therapy options include the induction of a synthetic solutions- the first is called EDTA (ethylenediaminetetraacetic acid) and is injected into the bloodstream to remove heavy metals and/or minerals from the body. [3] Another medication is DMSA (dimercaptosuccinic acid) which is recognized to mobilise and enhance the excretion of lead from the storage sites in the body that are most directly relevant to the health effects of lead. The intravenous application of DMPS (dimercapto-1-propanesulfonic acid) is most useful for the diagnosis of multiple metal overexposure. It is also the treatment of choice for Antimony (Sb), Arsenic (As), Cadmium (Cd), Lead (Pb), Mercury (Hg) and Copper (Cu) binding ability of the chelators tested. [4]
A provocative chelation test with DMSA could thus have wide potential application in clinical care and epidemiological studies. (see NCBI/NIH). Over-the-counter prescription versions are available for DMSA to rarely treat severe overdoses of lead and other heavy metal poisoning and the compounds of each are also available in health food stores as supplements.
Conclusion
Heavy metal and toxin-related
disease is no longer rare, and it is no longer theoretical. Modern
exposures—from food, implants, medical contrast agents, occupation, and
environment—are overwhelming detox pathways and silently driving inflammatory,
autoimmune, endocrine, and oncologic disorders. Traditional lab testing alone
cannot meet this challenge.
By adopting OligoScan as a fast, non-invasive screening tool
and following with ultrasound-based diagnostic confirmation and mapping,
Dr. Bard advances a clinically responsible and data-driven model: suspect
earlier, detect earlier, intervene earlier. The Starry Night signature and
associated imaging modalities extend this paradigm by visualizing what toxins
leave behind—changes in tissue, architecture, and microvasculature that can
finally be seen, measured, and tracked.
This two-tier approach—biochemical screening plus visual
diagnostics—represents a new pathway for precision environmental medicine,
giving clinicians actionable insight and patients a chance at prevention
instead of late discovery.
References
1. Grandjean
P, Landrigan PJ. Neurobehavioural effects of developmental toxicity. Lancet.
2014.
2. Rajpurkar
A, Jiang X. Heavy metals and chronic disease. Clin Rev Toxicol. 2020.
3. Filippini
T, et al. Mercury exposure and human health. Int J Environ Res Public
Health. 2018.
4. Runge
VM. Safety of Gadolinium-Based Contrast Agents. Top Magn Reson Imaging.
2016.
5. Weber
MA, et al. Ultrasound elastography in clinical practice. Radiology.
2018.
6. Bard
R. Clinical statements on OligoScan and Starry Night findings.
COPYRIGHT NOTICE
This article draft is an original work produced by the writing and editorial team of the AngioInstitute (a 501(c)(3) nonprofit organization), created exclusively for use, distribution, and publication by DetoxScan.org. All content contained herein, including written material, concepts, titles, and formatting, is the intellectual property of the AngioInstitute and is protected under United States and international copyright laws. Unauthorized reproduction, copying, distribution, transmission, or republication of any portion of this material—whether in print, digital, or any other format—is strictly prohibited without prior written permission from the copyright holder. The AngioInstitute retains full ownership of the content until and unless formally transferred in writing. This draft may not be altered, adapted, or used in derivative works without express consent. All rights reserved. For inquiries regarding usage, permissions, or content licensing, please contact the AngioInstitute directly.
